Trial Outcomes & Findings for Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer (NCT NCT00100828)

Results Overview

To determine the response rate of this regimen of irinotecan in patients with metastatic MTC

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

6 participants

Primary outcome timeframe

Every 2 cycles

Results posted on

2018-12-06

Participant milestones
Measure	Irinotecan irinotecan hydrochloride
Overall Study STARTED	6
Overall Study COMPLETED	0
Overall Study NOT COMPLETED	6

Reasons for withdrawal
Measure	Irinotecan irinotecan hydrochloride
Overall Study Physician Decision	6

Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer

Baseline characteristics by cohort
Measure	Irinotecan n=6 Participants irinotecan hydrochloride
Age, Categorical <=18 years	0 Participants n=99 Participants
Age, Categorical Between 18 and 65 years	4 Participants n=99 Participants
Age, Categorical >=65 years	2 Participants n=99 Participants
Age, Continuous	71 years STANDARD_DEVIATION 10.94 • n=99 Participants
Sex: Female, Male Female	2 Participants n=99 Participants
Sex: Female, Male Male	4 Participants n=99 Participants
Region of Enrollment United States	6 participants n=99 Participants

Timeframe: Every 2 cycles

Population: Study was closed to enrollment due to low accrual. Data was not collected for this outcome measure.

To determine the response rate of this regimen of irinotecan in patients with metastatic MTC

Outcome data not reported

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

SKCCC at Johns Hopkins

Phone: 410-955-9818